0
Cardiovascular Disease |

The Effects of Phosphodiesterase 5 Inhibition on Hemodynamics, Functional Status, and Survival in Advanced Heart Failure and Pulmonary Hypertension: A Case-Control Study

Hikmet Al-Hiti*, PhD; Vojtech Melenovsky, PhD; Adrian Reichenbach, MD; Ivan Malek, PhD; Jan Pirk, PhD; Eva Goncalvesova, PhD; Josef Kautzner, PhD
Author and Funding Information

IKEM, Prague, Czech Republic


Chest. 2012;142(4_MeetingAbstracts):79A. doi:10.1378/chest.1382371
Text Size: A A A
Published online

Abstract

SESSION TYPE: Heart Failure

PRESENTED ON: Sunday, October 21, 2012 at 10:30 AM - 11:45 AM

PURPOSE: The goal was to examine the hemodynamic and clinical effects of long-term therapy with PDE5 inhibitor sildenafil (SILD) in patients with advanced, pre-transplant heart failure (HF) and severe pulmonary hypertension (PH),in comparison to a similar control group (CON).

METHODS: In this matched case-control study, 32 middle-aged patients (81% males) with advanced systolic HF (80%≥NYHA III, 56% ischemic) and severe pre-capillary PH (transpulmonary pressure gradient>15 mmHg) were studied before and after initiation of SILD (dose 73±25mg/day) and were compared to 15 CON patients, matched for key clinical characteristics (including PH severity, age and co-morbidities), not exposed to SILD. Changes at 3 months and the long-term outcome were compared between groups

RESULTS: SILD significantly reduced pulmonary vascular resistance (-32% vs. baseline), transpulmonary gradient (-25%) and increased cardiac output (+15%) compared to controls, without affecting systemic or ventricular filling pressures. SILD-treated subjects experienced an improvement in NYHA class and had a steady body weight which contrasted with significant weight loss in the CON group (by -4.8%, absolutely by 4.3±6 kg). During followup (median 914 days), overall survival was significantly better in the SILD than the CON group (85% vs. 56%, p=0.04). Sixty percent of patients underwent heart transplantation. Among them, two patients in the CON group had severe post-transplant failure of the right ventricle while none did in the SILD group.

CONCLUSIONS: In patients with advanced HF and severe PH, SILD therapy has beneficial effects on hemodynamics, clinical status, cardiac cachexia, and contributes to improved peritransplant survival

CLINICAL IMPLICATIONS: Therapy with PDE5 inhibitors in patients with advanced HF and severe PH has beneficial effect on hemodynamics, clinical status and body weight loss due to cardiac cachexia.

DISCLOSURE: The following authors have nothing to disclose: Hikmet Al-Hiti, Vojtech Melenovsky, Adrian Reichenbach, Ivan Malek, Jan Pirk, Eva Goncalvesova, Josef Kautzner

No Product/Research Disclosure Information

IKEM, Prague, Czech Republic

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543